ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2024 · 110 positions · Total reported value $4.87B · Top-10 concentration 45.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2024 13F filing, ORBIMED ADVISORS LLC disclosed 110 equity positions with a combined reported value of $4.87B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 45.7% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were SVA ($340.00M), LLY ($305.66M), EWTX ($270.54M). By sector, the heaviest allocations are Health Care 79.8%, Industrials 1.5%. Versus the prior quarter, allocation shifted toward Health Care (+2.8pp) and away from Consumer Discretionary (-0.6pp), Other (-2.1pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 82% of names.

The largest new positions opened in Q2 2024 were ALNY ($60.82M), ITGR ($40.44M), ADCT ($13.64M).

Of the 23 positions fully exited versus the prior quarter, the largest were ALPN ($106.25M), ESPR ($36.74M), PRAX ($28.10M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • ALNY ALNYLAM PHARMACEUTICALS INC · $60.82M
  • ITGR INTEGER HLDGS CORP COM · $40.44M
  • ADCT ADC THERAPEUTICS SA SHS · $13.64M
  • SOLV SOLVENTUM CORP COM SHS · $10.58M
  • PFE PFIZER INC · $7.00M
  • CCCC C4 THERAPEUTICS INC · $6.99M
  • GPCR STRUCTURE THERAPEUTICS INC · $4.91M
  • MRUS MERUS N V · $2.96M

Fully Exited (vs previous quarter)

  • ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $106.25M
  • ESPR ESPERION THERAPEUTICS INC NE · prev qtr: $36.74M
  • PRAX PRAXIS PRECISION MEDICINES INC COM NEW · prev qtr: $28.10M · history
  • KNTE KINNATE BIOPHARMA INC · prev qtr: $21.31M
  • ARWR Arrowhead Pharmaceuticals In · prev qtr: $21.15M
  • AVTE AEROVATE THERAPEUTICS INC · prev qtr: $16.72M
  • VTYX VENTYX BIOSCIENCES INC · prev qtr: $10.29M
  • TXG 10X GENOMICS INC · prev qtr: $8.45M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 79.8%
Other 17.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.72M $340.00M 6.98%
6.98%
Hold
2 337.60K $305.66M 6.27%
6.27%
Reduce
3 15.02M $270.54M 5.55%
5.55%
Hold
4 3.27M $252.05M 5.17%
5.17%
Hold
5 493.10K $219.36M 4.50%
4.50%
Hold
6 900.90K $208.85M 4.29%
4.29%
Hold
7 7.96M $186.01M 3.82%
3.82%
Reduce
8 1.32M $162.92M 3.34%
3.34%
Hold
9 1.17M $156.08M 3.20%
3.20%
Hold
10 2.98M $124.82M 2.56%
2.56%
Reduce
11 2.37M $113.07M 2.32%
2.32%
Add
12 269.00K $91.53M 1.88%
1.88%
Hold
13 168.10K $91.09M 1.87%
1.87%
Hold
14 209.10K $89.92M 1.84%
1.84%
Add
15 1.79M $80.48M 1.65%
1.65%
Add
16 9.24M $78.64M 1.61%
1.61%
Hold
17 5.78M $75.13M 1.54%
1.54%
Hold
18 687.50K $74.45M 1.53%
1.53%
Reduce
19 132.00K $73.00M 1.50%
1.50%
Hold
20 151.00K $70.78M 1.45%
1.45%
Add
21 1.71M $64.32M 1.32%
1.32%
Hold
22 448.20K $61.70M 1.27%
1.27%
Add
23 250.30K $60.82M 1.25%
1.25%
New
24 795.90K $60.10M 1.23%
1.23%
Reduce
25 1.27M $57.98M 1.19%
1.19%
Hold
26 1.28M $57.37M 1.18%
1.18%
Reduce
27 112.00K $57.04M 1.17%
1.17%
Add
28 3.03M $56.16M 1.15%
1.15%
Hold
29 174.10K $54.58M 1.12%
1.12%
Hold
30 7.62M $51.89M 1.06%
1.06%
Hold
31 1.30M $49.98M 1.02%
1.02%
Add
32 2.61M $49.82M 1.02%
1.02%
Hold
33 73.11M $46.06M 0.94%
0.94%
Hold
34 812.91K $44.04M 0.90%
0.90%
Add
35 134.90K $42.15M 0.86%
0.86%
Add
36 10.91M $41.56M 0.85%
0.85%
Hold
37 2.86M $41.38M 0.85%
0.85%
Reduce
38 2.25M $40.44M 0.83%
0.83%
Hold
39 349.22K $40.44M 0.83%
0.83%
New
40 1.93M $39.53M 0.81%
0.81%
Add
41 862.36K $33.62M 0.69%
0.69%
Add
42 289.90K $32.87M 0.67%
0.67%
Add
43 12.05M $32.15M 0.66%
0.66%
Hold
44 704.84K $28.94M 0.59%
0.59%
Hold
45 706.48K $28.86M 0.59%
0.59%
Reduce
46 672.42K $28.41M 0.58%
0.58%
Add
47 3.41M $25.75M 0.53%
0.53%
Reduce
48 708.40K $25.00M 0.51%
0.51%
Hold
49 675.87K $24.45M 0.50%
0.50%
Hold
50 5.56M $24.18M 0.50%
0.50%
Hold

FAQ

What did ORBIMED ADVISORS LLC buy in 2024-Q2?

In its 2024-Q2 13F filing, ORBIMED ADVISORS LLC reported 110 equity positions worth $4.87B in aggregate; its largest disclosed positions were SVA ($340.00M), LLY ($305.66M), EWTX ($270.54M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $4.87B of long equity holdings across 110 positions as of 2024-Q2. Top-10 holdings account for 45.7% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →